Immunomedics reports initial clinical experience with epratuzumab ... pharmabiz.com ... unless they are combined with chemotherapy, such as rituximab + CHOP (R- ... and rituximab + hyper-fractionated CVAD for mantle cell lymphoma (MCL). |
Immunomedics reports initial clinical experience with epratuzumab ... pharmabiz.com ... unless they are combined with chemotherapy, such as rituximab + CHOP (R- ... and rituximab + hyper-fractionated CVAD for mantle cell lymphoma (MCL). |